Fecal microbiota transplant for Crohn disease: A study evaluating safety, efficacy, and microbiome profile

Gutin, Liat; Piceno, Yvette; Fadrosh, Douglas; Lynch, Kole; Zydek, Martin; Kassam, Zain; LaMere, Brandon; Terdiman, Jonathan P.; Ma, Averil; Somsouk, Ma; Lynch, Susan V.; El-Nachef, Najwa

doi:10.1177/2050640619845986

Cited by 54 publications

(52 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Crohn’s disease (CD) is a chronic inflammatory disease that is considered to result from a complex interplay between genetic susceptibility, environmental factors and altered gut microbiota. The therapeutic potential of faecal microbiota transplantation (FMT) in CD has recently been demonstrated (Gordon and Harbord, ; Kao et al , ; Suskind et al , ; Cui et al ., ; Vaughn et al , ; Gutin et al , ). In our pilot study between 2012 and 2014, 86.7% and 76.7% of patients with refractory CD achieved clinical improvement and remission at 1 month after a single FMT through mid‐gut respectively (Cui et al ., ).…”

Section: Introductionmentioning

confidence: 98%

Efficacy of faecal microbiota transplantation in Crohn’s disease: a new target treatment?

Xiang

Ding

et al. 2020

Microbial Biotechnology

View full text Add to dashboard Cite

Summary The efficacy of faecal microbiota transplantation (FMT) in Crohn’s disease (CD) remains unclear due to lack of data. This study aimed to assess the value of FMT in treating CD‐related clinical targets. The use of FMT for CD as a registered trial (NCT01793831) was performed between October 2012 and December 2017. Seven therapeutic targets included abdominal pain, diarrhoea, hematochezia, fever, steroid‐dependence, enterocutaneous fistula and active perianal fistula. Each target was recorded as 1 (yes) or 0 (no) during the long‐term follow‐up for each patient. The primary outcome was the rate of improvement in each therapeutic target. Overall, 174 patients completed the follow‐up. The median follow‐up duration was 43 (interquartile range, 28–59) months. The median score of the total targets was 2 (range, 1–4) before FMT, and it decreased significantly at 1, 3, 6, 12, 24 and 36 months after FMT (P < 0.001 respectively). At 1 month after FMT, 72.7% (101/139), 61.6% (90/146), 76% (19/25) and 70.6% (12/17) of patients achieved improvement in abdominal pain, diarrhoea, hematochezia and fever respectively. Furthermore, 50% (10/20) of steroid‐dependent patients achieved steroid‐free remission after FMT. The present findings indicate that it is important to understand the efficacy of FMT in CD as a targeted therapy, especially for abdominal pain, hematochezia, fever and diarrhoea.

show abstract

Section: Introductionmentioning

confidence: 98%

Efficacy of faecal microbiota transplantation in Crohn’s disease: a new target treatment?

Xiang

Ding

et al. 2020

Microbial Biotechnology

View full text Add to dashboard Cite

show abstract

“…The evidence on the effect of FMT in CD has recently been presented. There are currently several active trials studying the effectiveness of FMT for CD, and the results are diverse ( Table 2) (Cui et al, 2015;Suskind et al, 2015;Wei et al, 2015;Vaughn et al, 2016;Vermeire et al, 2016;Goyal et al, 2018;Gutin et al, 2019;Sokol et al, 2020;Xiang et al, 2020). Xiang et al (2020) studied 174 CD patients treated with FMT via Mid-gut including nasojejunal tube, endoscopy and mid-gut TET (except one through colonic TET).…”

Section: Crohn's Diseasementioning

confidence: 99%

Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Tan

Shen

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients.

show abstract

“…First study showed that FMT was safe and no serious adverse events were observed. However, in the second study 2 out of 10 patients they occured in significant level [31,32] Sixty-nine patients with CD who underwent and responded to FMT in the past were enrolled in Pan Li et al study. This study aimed to evaluate the optimal timing for performing FMT second time to maintain the long-term clinical effects in patients with CD.…”

Section: The Use Of Fmt In Crohn's Diseasementioning

confidence: 99%

The use of fecal microbiota transplantation in the treatment of intestinal diseases

Ręka¹,

Nowak²,

Psiuk³

et al. 2020

J Educ Health Sport

View full text Add to dashboard Cite

Introduction and purpose Fecal microbiota transplantation (FMT) is a process of transferring gut microflora from a healthy donor to a recipient. It is indicated that the human distal gastrointestinal tract consists of more than 1000 species of bacteria, which have an impact on local and systemic processes related to immunity, nutrition and the gut-brain axis. The growth of new bacterial species, reduction of microbial variety or big changes in the ratio between them can lead to a dysbiosis. The relationship between intestinal microbiota and some systemic diseases is seen. The study aimed to present the state of knowledge on FMT in the treatment of intestinal diseases. Publications from the last 5 years from the Pubmed database were included. A brief description of the state of knowledge Intestinal diseases constitute the main group of indications for FMT. FMT can be delivered via upper or lower gastrointestinal routes. The review presents different studies concerning the usage of FMT. Among them, recurrent Clostridium difficile infection, colitis ulcerosa, Crohn's disease and irritable bowel syndrome are mainly indicated in the literature. FMT might find its application also in a treatment of multidrug-resistant organisms colonization, antibiotic-associated diarrhea, gut acute graft-versus-host disease and radiation enteritis. There is a possibility of the occurrence of adverse events from the digestive tract after FMT. However, the studies evaluate them as mostly mild and transient. In some cases it was necessary to repeat FMT to achieve a satisfactory final result. Conclusions Fecal microbiota transplantation gives hope for a safe and effective method of treatment of certain intestinal diseases. There is a need for conducting further analysis of the method.

show abstract

Fecal microbiota transplant for Crohn disease: A study evaluating safety, efficacy, and microbiome profile

Cited by 54 publications

References 18 publications

Efficacy of faecal microbiota transplantation in Crohn’s disease: a new target treatment?

Efficacy of faecal microbiota transplantation in Crohn’s disease: a new target treatment?

Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

The use of fecal microbiota transplantation in the treatment of intestinal diseases

Contact Info

Product

Resources

About